Member Info for Energyshares

The AVA6000 is going to be data rich and Avacta only need a improvement in any of the studies below for success.

Can’t be long now before the other 3 hospitals start recruiting, and we are now coming up to 6 months running.

Data

Elimination half-life (t1/2) of AVA6000 & Doxorubicin

Progression-free-survival (PFS)

Objective response rate (ORR)

Duration of Response (DoR)

Maximum drug concentration (Cmax) of AVA6000 & Doxorubicin

Overall survival (OS)

Renal clearance (CLr) of AVA6000 & Doxorubicin

Area under the concentration versus time curve (AUC) of AVA6000 & Doxorubicin

https://www.patientwing.com/study/386687?showAdvancedDetails=true

Rippers
You know you will have to make merchant w…anker coffee every morning now until you sell…. :)

Abdx ain’t going to give up on that substantial order from Avacta they will be working flat out to solve this problem.

Which solves their cash flow problem.

Reaper,
I like your analysis of the RNS,keep posting very interesting.

Doh,
A bit a dig with the Kopite scum we did give you agent Rafa,
My view sell diagnostics to Medusa for a billion and life time supply of shumpers for Big Al.
Concentrate on therapeutics :)

Drops 33% no brakes on. Goes up 7p and brakes go on,can any one explain.

If Medusa knew about today’s bombshell why did they change the website wording to include Omicron last Friday.
They could of just left the old wording that didn’t mention Omicron.

MeduFlow® contains unique and proprietary Affimer® technology from Avacta creating synthetic antibodies to create more binding sites for the virus, leading to excellent sensitivity and specificity.
MeduFlow® is validated against delta and omicron variants, and Medusa19 are constantly monitoring all emerging variants to ensure continued diagnostic accuracy.

33.62% down and no brakes put on:
Can anyone explain why no
RNS Price Monitoring Extensions today.

They just issued a RNS

Avacta has exceptional IP, what are the odds of a chancer Pharma trying to snatch it away with a cheeky bid…..

I hope they can sort this LFT mess out very quickly before it happens.

This one deal is worth 33% more than the value of the company.
Ridiculous situation……..

In December 2018, Avacta and LG Chem entered into a multi-target therapeutics development agreement to develop Affimer® therapeutics in several disease areas potentially worth over $300m to Avacta. The companies have today agreed to expand this drug development partnership to include Avacta's Affimer XTTM technology, which can be used to control the time a drug spends in the circulation.

The way AS is playing with RNS’s and not trying to manage impact on SP is very risky.
MCap is just £214m now is is ripe for a opportunist bidder considering the IP Avacta own.
Hope he knows what he’s doing…

So pridective txt i meant threw this out before good news

AS knew this would hit the SP,
So I reckon he has three this out before some massive AVA6K news to rebound this SP.

Otherwise he would of told us before Xmas

Just topped into my ISA @ 0.91
Happy with that with news coming on AVA6 k

Could this tweak be for FDA

Abdx RNS
Abingdon scientists will work with Avacta to accelerate the process of replacing the antibody in the current assay format, and complete the process of technology transfer with this new specification.

So mid Dec TT complete nearly two weeks into New Year, they could have new affimer ready next week this could be a masterstroke by Avacta or it could come back and bite.

Timster
Can’t we even get a trade deal of Biden and it won’t bode well that UK Gov are totally ignoring US & FDA recommendations on throwing the China 5h1te in the bin.

I actually think this could work in Avacta’s favour.

Coming soon launch price £14.99
https://agiletestservices.com/pages/about-us

You never know Yanks might want all you can make. :)